N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Aligning With Schools To Help Manage Asthma (Project ASTHMA)
Asthma
Primary: Change in Number of Days Per Week, in the Previous 4 Weeks, of Daytime Asthma Symptoms From Baseline to 7-month Follow-up — -3.4; -2.8 days per week
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Early Phase 1 N=39 Defining and Treating Depression-related Asthma
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
N/A N=18 Airway Smooth Muscle and Asthma Severity
Asthma
Primary: Difference in ASM Mass Between Groups
Early Phase 1 N=9 In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
N/A N=351 Allergens in Inner-City Schools and Childhood Asthma
Asthma
Primary: Maximum Symptom Days/14 Days — 2.7 days
Phase 4 N=222 An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma
Primary: Percentage of Participants From Each Stratum Who Demonstrated Correct Use of the ELLIPTA DPI at Visit 2, Attempt 1 (Day 28) — 92; 93 Percentage of participants
Phase 3 N=211 Characterization of the Role of Histamine in Children With Asthma
Asthma · Allergic Asthma · Non-allergic Asthma
Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale
N/A N=66 Academic Achievement in Children With Asthma
Asthma
Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)
Phase 2 N=15 PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — 2.624; 2.626; 2.585; 2.579 L
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=11 Flexibility and Strength Training in Asthma
Asthma
Primary: Forced Expiratory Volume at One Second - FEV1 % Predicted — 91.4; 93.4 % predicted — p=.10
Phase 3 N=210 Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
Asthma
Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute
N/A N=33 Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics
Allergic Asthma
Primary: Effect of Natural-source d-α-tocopheryl Acetate on the Baseline and Allergen-induced Levels of F2-isoprostanes in the Bronchoalveolar Lavage Fluid (BAL)
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
N/A N=13 Dietary Supplementation With Soy Isoflavones in Asthma
Asthma
Primary: Exhaled Nitric Oxide — 67.0; 54.8 parts per billion (ppb) — p=<0.03
Phase 4 N=259 Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma
Asthma
Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…
N/A N=222 Asthma Express: Bridging the Emergency to Primary Care in Underserved Children
Asthma
Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
N/A N=36 Exercise Training in Asthma Children
Asthma
Primary: Exhaled Nitric Oxide (FeNO) Level — 29.3; 23.3 ppb
Phase 3 N=1,162 Montelukast Back to School Asthma Study (0476-340)
Asthma
Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
Phase 2 N=35 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
Asthma
Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…
N/A N=292 Asthma in Central Texas Project
Asthma
Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled
Phase 2 N=16 The Use of Rosiglitazone to Treat Asthma
Asthma
Primary: Methacholine Responsiveness as Assessed by PC20, — 3.27; 8.71 mg/mL — p=0.048
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…